ECM1 and cancer: Similarly, we found that LA/DC-CTL could generate remarkable cytotoxicity against HLA-A2.1+/ECM1+ primary cancer cells and microtissue blocks derived from fresh clinical specimens (Fig. 2h, i, k, Additional file 1: Fig. S4).